Cargando…

Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation

Cancer arises through accumulation of epigenetic and genetic alteration. Aberrant promoter methylation is a common epigenetic mechanism of gene silencing in cancer cells. We here performed genome-wide analysis of DNA methylation of promoter regions by Infinium HumanMethylation27 BeadChip, using 14 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kikuchi, Yasuko, Tsuji, Eiichi, Yagi, Koichi, Matsusaka, Keisuke, Tsuji, Shingo, Kurebayashi, Junichi, Ogawa, Toshihisa, Aburatani, Hiroyuki, Kaneda, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851831/ https://www.ncbi.nlm.nih.gov/pubmed/24367375 http://dx.doi.org/10.3389/fgene.2013.00271

Ejemplares similares

Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway
por: Sakai, Eiji, et al.
Publicado: (2015)

Activation of Bmp2-Smad1 Signal and Its Regulation by Coordinated Alteration of H3K27 Trimethylation in Ras-Induced Senescence
por: Kaneda, Atsushi, et al.
Publicado: (2011)

Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients
por: Takane, Kiyoko, et al.
Publicado: (2014)

Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
por: Lim, Jinsun, et al.
Publicado: (2023)

A simple knowledge-based mining method for exploring hidden key molecules in a human biomolecular network
por: Tsuji, Shingo, et al.
Publicado: (2012)

Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection
por: Funata, Sayaka, et al.
Publicado: (2017)

Efficacy of octreotide against chylothorax following lateral neck dissection for thyroid cancer: A case report
por: Hayashibara, Noriaki, et al.
Publicado: (2016)

Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report
por: Ishizuna, Kazuo, et al.
Publicado: (2014)

TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection
por: Namba-Fukuyo, Hiroe, et al.
Publicado: (2016)

Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer
por: Matsusaka, Keisuke, et al.
Publicado: (2016)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis
por: Yamamoto, Yosuke, et al.
Publicado: (2020)

A case of breast cancer in the axillary tail of Spence – enhanced magnetic resonance imaging and positron emission tomography for diagnostic differentiation and preoperative treatment decision
por: Okubo, Mai, et al.
Publicado: (2013)

PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer
por: Sato, Teruyuki, et al.
Publicado: (2013)

Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens
por: Matsusaka, Keisuke, et al.
Publicado: (2016)

Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease
por: Tsuji, Shingo, et al.
Publicado: (2021)

Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features
por: Dolezal, James M., et al.
Publicado: (2020)

BRAF Testing in Multifocal Papillary Thyroid Carcinoma
por: Kimbrell, Hillary Z., et al.
Publicado: (2015)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis
por: Takane, Kiyoko, et al.
Publicado: (2016)

TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors
por: Sakai, Eiji, et al.
Publicado: (2016)

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
por: Melck, Adrienne L., et al.
Publicado: (2010)

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
por: Brastianos, Priscilla K., et al.
Publicado: (2014)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
por: Okabe, Atsushi, et al.
Publicado: (2021)

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells
por: Arozarena, Imanol, et al.
Publicado: (2014)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
por: Zhao, Yiqing, et al.
Publicado: (2021)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding
por: Martinez Fiesco, Juliana A., et al.
Publicado: (2022)

Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
por: Trebino, Tarah, et al.
Publicado: (2023)

High expression of CXCL14 is a biomarker of lung adenocarcinoma with micropapillary pattern
por: Sata, Yuki, et al.
Publicado: (2020)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients with Acromegaly
por: Kim, Hee Kyung, et al.
Publicado: (2014)

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
por: Bonaldi, Elisa, et al.
Publicado: (2021)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
por: Yang, Li-Bo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rti04cnv3flgfq77kj2rqqnnpv